[Drug-induced exudative erythema multiforme major with a chronic progressive course and bilateral blindness. Clinical and immunohistologic follow-up].
A 24-year-old male patient who had been received Fansidar developed exudative erythema multiforme major with massive involvement of the skin, mucous membranes, and both eyes. The chronic inflammation led to proliferation of the conjunctiva, with keratinization of the ocular surface and corneal vascularization. The final result was comparable to cicatricial pemphigoid, with blindness of both eyes. In histological sections, massive lympho-plasma-cellular infiltration with circumscribed perivasculitis was seen. The lymphocyte transformation test was still positive 18 months after onset of the disease. Class II antigens were evident in some of the conjunctival biopsies.
Thiel
H J
HJ
Univ.-Augenklinik Tübingen, Abt. I: Allgemeine Augenheilkunde mit Poliklinik.
Richter
U
U
Pleyer
U
U
Zierhut
M
M
Steuhl
K P
KP
D000328:Adult; D000962:Antimalarials; D001766:Blindness / Q000139:chemically induced* / Q000473:pathology; D003228:Conjunctiva / Q000473:pathology; D004338:Drug Combinations; D003875:Drug Eruptions / Q000473:pathology*; D004848:Epithelium / Q000473:pathology; D005500:Follow-Up Studies; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008854:Microscopy, Electron; D009061:Mouth Mucosa / Q000473:pathology; D011739:Pyrimethamine / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000473:pathology; D013413:Sulfadoxine / Q000009:adverse effects*
D000962:Antimalarials; D004338:Drug Combinations; D000949:Histocompatibility Antigens Class II; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine
Arzneimittelinduziertes Erythema exsudativum multiforme majus mit chronisch-progressivem Verlauf und beiderseitiger Erblindung. Klinische und immunhistologische Verlaufsbeobachtung.